|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Arrowhead Acquires Novartis' RNAi Research and Development Portfolio
- Conference Call Today at 8:30 a.m. EST
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated assets. The acquisition includes assignment of certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, an exclusive license in the RNAi field to other patents and patent applications owned or controlled by Novartis, assignment of a third party license, three pre-clinical RNAi candidates, and other related assets. The company is hosting a conference call at 8:30 a.m. EST to discuss the acquisition.
Key aspects of the acquisition include the following:
Multiple patent families covering RNAi-trigger design rules and modifications that fall outside of key patents controlled by competitors, which the Company believes provides freedom to operate for any target and indication;
Novel intracellular targeting ligands that enhance the activity of RNAi-triggers by targeting the RNA-induced silencing complex (RISC) more effectively and improving stability once RISC is loaded;
An assignment of Novartis' license from Alnylam Pharmaceuticals granting Arrowhead access to Alnylam intellectual property, excluding delivery, for 30 gene targets chosen by Novartis;
A pipeline of three candidates initiated by Novartis and for which Novartis has developed varying amounts of preclinical data.
"This is an important deal for us. Novartis has been working in the RNAi field for over a decade and their developments in proprietary oligonucleotide formatting and modifications are some of the best we've seen. We anticipate this acquisition will provide us with substantially expanded freedom to operate, proprietary technology that appears to enhance the activity of RNAi triggers, access to non-delivery Alnylam RNAi IP for 30 targets, and three programs that went through the rigorous Novartis vetting process," said Christopher Anzalone, Ph.D., president and chief executive officer of Arrowhead. "We now have additional flexibility to optimize each new candidate using the most effective RNAi-trigger design and modifications. We look forward to incorporating these novel technologies into future drug candidates."
Under the terms of the agreement, Arrowhead previously made a payment to Novartis of $7 million in cash and will provide an additional payment of $3 million in cash and $25 million in Arrowhead common stock within 30 days. Novartis is also eligible to receive milestones and single digit royalties on sales of future products in connection with the agreement.
Conference Call and Webcast Details
To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 98554265. Investors may also access a live audio webcast of this conference call on the Company's website at http://ir.arrowheadresearch.com/events.cfm.
A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 7 days. The audio replay can be accessed by dialing 855-859-2056 (toll free from the US), or 404-537-3406 (for international callers) and entering Conference ID 98554265.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.
箭头收购诺华的RNAi技术研究和发展投资组合
- 电话会议今天在上午08时30分EST
加利福尼亚州帕萨迪纳 - （美国商业资讯） - 箭头研究公司（NASDAQ：ARWR），一家生物制药公司，开发有针对性的RNAi疗法，今天宣布收购诺华的整个RNAi技术的研究和开发的投资组合和相关资产。采集包括由诺华有关RNAi疗法，在RNAi的字段由Novartis，一个第三方许可分配，三临床前拥有或控制其他专利和专利申请的独家许可拥有或控制的某些专利转让和专利申请RNA干扰考生，以及其他相关资产。该公司正在举办一个电话会议上午8:30 EST洽谈收购。
收购的主要方面包括以下内容：
多个专利涵盖家庭RNA干扰触发的设计规则和竞争对手，该公司相信提供了自由操作的任何目标和指标控制关键专利落在外面的修改;
新颖的细胞内靶向一旦RISC加载RNA诱导的沉默复合物（RISC）更有效和改进稳定性的靶向配体增强的RNAi的触发器的活性;
从Alnylam制药授予箭头获得Alnylam公司的知识产权，不包括交付，由诺华选择30靶基因诺华牌照转让;
由诺华公司和诺华公司发起的三名候选人一个管道已开发数量不等的临床前数据。
“这对我们来说是一个重要的交易。诺华一直在RNA干扰领域超过十年及其专有的寡核苷酸格式和修改进展是一些我们所见过的最好的。我们预计此次收购将为我们提供大幅扩大自由操作，专有技术，似乎增强的RNAi触发器的活动，获得未送达Alnylam公司的RNAi IP 30的目标，和三个方案，经过严格的诺华审批去了，说：“克里斯托弗Anzalone，博士，总裁和箭头的首席执行官。 “我们现在有更多的灵活性，采用最有效的RNA干扰触发的设计和修改，优化每一个新的候选人。我们期待着将这些新技术整合到未来的候选药物。”
根据协议条款，此前慈姑做支付700万美元的现金，以诺华将提供额外支付300万美元现金和2500万美元的箭头普通股股票在30天内。诺华也有资格获得里程碑和个位数的特许权使用费，销售收入未来产品与协议有关。
电话会议和网络直播详情
要参加电话会议，请拨打855-215-6159（免费电话从美国）或315-625-6887（国际用户）并输入会议ID 98554265.投资者还可以访问此电话会议的现场录音网络直播在公司网站http://ir.arrowheadresearch.com/events.cfm。
该网络广播的重播将在电话会议结束后约两小时，并会保持可用90天。音频重播也将是可利用的呼叫结束之后大约两个小时，将可为7天。音频重播可以通过拨打855-859-2056（免费电话从美国）或404-537-3406（国际用户）并输入会议ID 98554265进行访问。
关于箭头研究公司
箭头研究公司是一家生物制药公司，开发有针对性的RNAi疗法。该公司利用其专有的动态Polyconjugate™交付平台开发基于能够有效地沉默致病基因的RNA干扰机制的靶向药物。箭头的管道包括ARC-520慢性乙肝病毒，ARC-AAT与α-1抗胰蛋白酶缺乏症，和合作伙伴为基础的方案在肥胖和肿瘤相关的肝脏疾病。
欲了解更多信息，请访问http://www.arrowheadresearch.com，或关注我们的微博@ArrowRes。要添加到该公司的电子邮件列表，并直接收到的消息，请访问http://ir.arrowheadresearch.com/alerts.cfm。 |
|
楼主: 林伍伍
发表于 2015-3-5 17:50
